memantine has been researched along with Dizzyness in 8 studies
Excerpt | Relevance | Reference |
---|---|---|
"Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease." | 5.62 | [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021) |
"Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist." | 3.80 | A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). ( Möbius, HJ; Stöffler, A; Wilcock, G, 2002) |
"The primary objective was to assess the safety and tolerability of rivastigmine capsules 6-12 mg/day plus memantine (5-20 mg/day) as measured by the incidences of vomiting and nausea compared with those reported in the rivastigmine United States Prescribing Information (US PI)." | 3.76 | Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). ( Bhatnagar, V; Brannan, S; Koumaras, B; Meng, X; Olin, JT; Reyes, P, 2010) |
" In addition, many adverse reactions were observed in these patients." | 2.82 | Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. ( Brassat, D; Brochet, B; Cabre, P; Castelnovo, G; Clavelou, P; Coman, I; Creveuil, C; Daplaud, D; De Seze, J; Debouverie, M; Defer, G; Dupuy, B; Hautecoeur, P; Heinzlef, O; Lebiez, P; Lebrun-Frenay, C; Pelletier, J; Peyro Saint Paul, L; Sartori, É; Tourbah, A; Vermersch, P, 2016) |
"Memantine was well tolerated with a frequency of adverse events comparable to placebo." | 2.70 | Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). ( Forette, F; Möbius, HJ; Orgogozo, JM; Rigaud, AS; Stöffler, A, 2002) |
"Memantine was found to have a favourable tolerability profile when used as monotherapy or in combination with other agents." | 2.46 | A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. ( Jones, RW, 2010) |
"Dizziness is not a unique clinical picture, but rather is the unspecific symptom of numerous diseases." | 2.44 | [Frequently occurring forms of dizziness and their treatment]. ( Thömke, F, 2007) |
"Memantine (Mem) is a non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist used in the treatment of Alzheimer's disease." | 1.62 | [Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment]. ( Aoki, Y; Han, LK; Kaneda, M; Michihara, S; Shimoyama, T; Takahashi, R, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (50.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Shimoyama, T | 1 |
Aoki, Y | 1 |
Kaneda, M | 1 |
Han, LK | 1 |
Michihara, S | 1 |
Takahashi, R | 1 |
Peyro Saint Paul, L | 1 |
Creveuil, C | 1 |
Heinzlef, O | 1 |
De Seze, J | 1 |
Vermersch, P | 1 |
Castelnovo, G | 1 |
Cabre, P | 1 |
Debouverie, M | 1 |
Brochet, B | 1 |
Dupuy, B | 1 |
Lebiez, P | 1 |
Sartori, É | 1 |
Clavelou, P | 1 |
Brassat, D | 1 |
Lebrun-Frenay, C | 1 |
Daplaud, D | 1 |
Pelletier, J | 1 |
Coman, I | 1 |
Hautecoeur, P | 1 |
Tourbah, A | 1 |
Defer, G | 1 |
Olin, JT | 1 |
Bhatnagar, V | 1 |
Reyes, P | 1 |
Koumaras, B | 1 |
Meng, X | 1 |
Brannan, S | 1 |
Jones, RW | 1 |
Wilcock, G | 1 |
Möbius, HJ | 2 |
Stöffler, A | 2 |
Thömke, F | 1 |
Orgogozo, JM | 1 |
Rigaud, AS | 1 |
Forette, F | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Effects of Memantine on Cognitive Disorders of Relapsing-remitting Multiple Sclerosis[NCT01074619] | Phase 3 | 90 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia[NCT00545974] | Phase 4 | 81 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.[NCT00196703] | Phase 4 | 30 participants | Interventional | 2005-03-31 | Recruiting | ||
A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.[NCT00640198] | Phase 4 | 28 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. A screening question is asked about each sub-domain. If the responses to these questions indicate that the patient has problems with a particular sub-domain of behavior, the caregiver is only then asked all the questions about that domain, rating the frequency of the symptoms on a 4-point scale, their severity on a 3-point scale, and the distress the symptom causes them on a 5-point scale. Severity(1=Mild to 3=Severe),frequency(1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144);higher score=greater behavioral disturbances;negative change score from baseline=improvement. (NCT00545974)
Timeframe: Baseline, 26 weeks
Intervention | units on a scale (Mean) |
---|---|
Memantine | -1.9 |
Placebo | 0.3 |
The scale is rated on a 7-point scale, using a range of responses from 1 (very much improved) through 7 (very much worse). The clinician compares the participant's current condition to the condition at admission to the project. (NCT00545974)
Timeframe: 26 Weeks
Intervention | units on a scale (Mean) |
---|---|
Memantine | 4.4 |
Placebo | 4.8 |
(NCT00545974)
Timeframe: 26 weeks
Intervention | Participants (Count of Participants) |
---|---|
Memantine | 1 |
Placebo | 2 |
"Clinical dementia rating sum of boxes CDR-SB (0-18) high scores indicate high impairment.~Functional activities questionnaire FAQ (0-30) high scores indicate high impairment.~Texas functional living scale TFLS (0 to 52) high scores suggest better instrumental activities of daily living functioning.~Mini-Mental State Examination MMSE (0-30) low scores indicate low cognition. The executive interview EXIT25 (0 to 50) high scores indicate more executive impairment.~A modified unified Parkinson's disease rating scale UPDRS (0-199) high scores indicate worse disability.~Boston naming test (0-15) low scores indicate more retrieval difficulties." (NCT00545974)
Timeframe: Baseline and 26 Weeks
Intervention | units on a scale (Mean) | ||||||
---|---|---|---|---|---|---|---|
CDR-SB | FAQ | TFLS | MMSE | EXIT25 | UPDRS | Boston naming test | |
Memantine | 1.5 | 4.3 | -3.7 | -1.2 | 1.9 | 1.7 | -1.4 |
Placebo | 1.5 | 2.9 | -2.8 | -0.9 | 0.7 | 1.4 | 0.7 |
"Letter fluency, score is number of words recalled starting with a specified letter for 60 seconds. There are 3 trials, with 3 different letters. The total number of correct responses is totaled for all 3 trials for the score. Low scores indicate high impairment~Category fluency, score is number of items generated belonging to a specific category (such as animals) in 60 seconds, low scores indicate high impairment.~Digit symbol, score is number of symbols that correctly corresponded to the random numerals entered in the form in 90 seconds. Participants are given a table of numerals with matching symbols, and a form with random numerals with open spaces. Low scores indicate high impairment.~Digits backwards, score is number of digits backwards recalled (range: 0-14), The participant hears a list of digits and is asked to repeat the digits backwards. Low scores indicate high impairment." (NCT00545974)
Timeframe: Baseline and 26 Weeks
Intervention | number of items recalled (Mean) | |||
---|---|---|---|---|
Letter fluency | Category fluency | Digit symbol | Digits backwards | |
Memantine | -0.1 | -0.5 | -3.9 | 0.1 |
Placebo | -0.3 | -0.7 | 4.2 | -0.2 |
3 reviews available for memantine and Dizzyness
Article | Year |
---|---|
A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors.
Topics: Aged; Akathisia, Drug-Induced; Alzheimer Disease; Cholinesterase Inhibitors; Dizziness; Drug Interac | 2010 |
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cognition; Dementia, Vascular; Dizziness; Double-Blin | 2002 |
[Frequently occurring forms of dizziness and their treatment].
Topics: Amines; Anticonvulsants; Betahistine; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnosis, Differe | 2007 |
3 trials available for memantine and Dizzyness
Article | Year |
---|---|
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Topics: Adult; Cognition Disorders; Dizziness; Double-Blind Method; Excitatory Amino Acid Antagonists; Femal | 2016 |
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cognition; Dementia, Vascular; Dizziness; Double-Blin | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).
Topics: Aged; Cognition; Dementia, Vascular; Disease Progression; Dizziness; Dopamine Agents; Double-Blind M | 2002 |
3 other studies available for memantine and Dizzyness
Article | Year |
---|---|
[Effects of Yokukansankachimpihange on Memantine-induced Dizziness in Mice with Memory Impairment].
Topics: Administration, Oral; Alzheimer Disease; Animals; Disease Models, Animal; Dizziness; Drug Therapy, C | 2021 |
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antipa | 2010 |
Memantine for Alzheimer's disease.
Topics: Alzheimer Disease; Dizziness; Dopamine Agents; Drugs, Investigational; Humans; Memantine; Randomized | 2003 |